According to Wood, the delay is ‘not technically a denial.. Thirteen senators have urged the Government Accountability Office, the FDA, and findings from its ongoing investigation into indefinite deferment FDA decision on Barr Laboratories ‘ application for nonprescription sales of its emergency contraceptive Plan B to publish women age 17 and older, CQ HealthBeat reports. Twelve Senate Democrats and Independent Sen. Jim the application the resignation of FDA Assistant Commissioner for Women ‘s Health Susan Wood, who resigned last week after the agency notice the delay.

– have ever used a needle to inject drugs, even if it was many years ago, hepatitis C. Transfusion or organ transplant before 1992, – have was on long-term dialysis, – is a Vietnam veteran, – have contact with blood on the skin, – had multiple sex partners, – tattoos or piercings have, – have liver disease; – have a history of drinking too much alcohol, or – have an abnormal liver tests – will be tested.The primary endpoint the study is objective response from start of treatment to 3 months after the last administration of ofatumumab assessed according to standardized response criteria the NHL Ice. Forward-looking statements Genmab A / S.. About the reportThe patients in this open-label trial were randomized to two dosage groups 28 patients per and obtained a total of 6 fluids ofatumumab in combination with CHOP. Each patient will 300mg ofatumumab in first infusion be followed by 5 subsequent infusions of either 500 or 1000 mg of ofatumumab followed by every 3 weeks in combination with 6 Operations CHOP. Disease status will be to assess three months after final treatment and be every three months until the month 24, and every 6 month thereafter.

Ofatumumab is into the development of new generation of human monoclonal antibody antibodies, one of said proximal membrane clear small loop epitope ties the CD20 molecule on the surface of B cells. Ofatumumab is being developed to the the treatment of CLL, follicular non -Hodgkin’s lymphoma, diffuse large B Lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis under a co – development and commercialization of between Genmab and Glaxo SmithKline. Open-labeluntry. Not yet permitted to sell in any country.